Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute - PR Newswire
INCLINE VILLAGE, Nev., and CHESHIRE, Conn., Jan. 5 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today jointly announced that the companies have entered into a definitive license ...

Dr. Martin Handfield Joins ONI BioPharma as Director, Research and ... - Genetic Engineering News
Oragenics, Inc. d/b/a ONI BioPharma Inc. ( OTCBB:ORNI ; Alternext Paris:ALONI), an American biopharmaceutical company, today announced that Dr. Martin Handfield has been appointed to the new position of Director, Research and Development. Prior to ...

PDL BioPharma, Alexion settle patent dispute - Boston Globe
NEW YORK— PDL BioPharma Inc. and Alexion Pharmaceuticals Inc. said Monday they settled a patent dispute over the blood disorder drug Soliris, in a cash for rights exchange. Soliris is Cheshire, Conn.-based Alexion's only marketed product. Approved ...

Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute - Phramalive.com
INCLINE VILLAGE, Nev., and CHESHIRE, Conn., January 05, 2009 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. and Alexion Pharmaceuticals, Inc. today jointly announced that the companies have entered into a definitive license agreement and settlement ...

UPDATE 1-Alexion, PDL BioPharma settle patent dispute - Reuters
Jan 5 (Reuters) - Alexion Pharmaceuticals Inc ( ALXN.O ) confirmed that its genetic disorder drug Solaris used technology covered by one of PDL BioPharma Inc ( PDLI.O ) patents and entered into a $25-million licensing deal with PDL. Under the ...

DOR BioPharma Receives SPA Clearance From the FDA to Begin ... - Genetic Engineering News
DOR BioPharma, Inc. (DOR or the Company) ( OTCBB: DORB ) announced today that it has reached agreement with the US Food and Drug Administration (FDA) on the design of a confirmatory, pivotal Phase 3 clinical trial evaluating its lead product orBec(R ...

Ambrilia Biopharma Submits a Request for Arbitration Against Merck - StreetInsider.com
MONTREAL, QUEBEC--(Marketwire - Dec. 30, 2008) - Ambrilia Biopharma Inc. (TSX: AMB ) announced today that it has submitted a Request for Arbitration with the International Chamber of Commerce (ICC) to resolve disputes, controversies and claims ...

Aspen BioPharma: Anticipating Active '09 - Seekingalpha.com
Now that AspenBio Pharma ( APPY ) has completed enrollment earlier this month in its FDA 510(k) clinical study for the world's first blood-based appendicitis screening test, AppyScore, investors will not have to wait much longer to get the results ...

Endo Shifts Gears With Indevus - Forbes
Endo Pharmaceuticals announced on Monday that it will be acquiring Indevus Pharmaceuticals in an effort to move away from its pain-management business and into something with a little less competition that is a bit more lucrative. Now that King ...

Ambrilia Biopharma submits request for arbitration in Merck case - Canada East
MONTREAL - Ambrilia Biopharma Inc. (TSX:AMB) said Tuesday that it has submitted a request for arbitration with the International Chamber of Commerce to resolve a dispute with Merck & Co. Inc. Ambrilia signed an exclusive licensing agreement granting ...